Gain Therapeutics, Inc. (GANX)
NASDAQ: GANX · Real-Time Price · USD
1.770
-0.025 (-1.39%)
At close: May 30, 2025, 4:00 PM
1.850
+0.080 (4.52%)
After-hours: May 30, 2025, 7:20 PM EDT
Gain Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
25
Market Cap
49.18M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
GANX News
- 2 days ago - Gain Therapeutics Announces Oral Presentation at 2nd GBA1 Meeting - GlobeNewsWire
- 17 days ago - Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update - GlobeNewsWire
- 19 days ago - Gain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson's Disease and Related Disorders - GlobeNewsWire
- 4 weeks ago - Gain Therapeutics to Participate at The Citizens Life Sciences Conference - GlobeNewsWire
- 4 weeks ago - Gain Therapeutics Announces Oral Poster Presentation at IAPRD 2025 30th World Congress on Parkinson's Disease and Related Disorders - GlobeNewsWire
- 2 months ago - Gain Therapeutics Announces Poster Presentation at AD/PD 2025 - GlobeNewsWire
- 2 months ago - Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2024 and Provides Corporate Update - GlobeNewsWire
- 2 months ago - Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson's Disease - GlobeNewsWire